2-(3-Benzyltriazolo[4,5-d]pyrimidin-7-yl)sulfanyl-5-pyridin-4-yl-1,3,4-oxadiazole

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-(3-Benzyltriazolo[4,5-d]pyrimidin-7-yl)sulfanyl-5-pyridin-4-yl-1,3,4-oxadiazole
• 化学式: C₁₈H₁₂N₈OS
• 分子量: 388.4
• InChiKey: RGURFBGDVHQYTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  134
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• Treatment and/or prevention of bone metastasis
  申请人：The Arizona Board of Regents on behalf of The University of Arizona

  公开号：US10179142B2

  公开（公告）日：2019-01-15

  T-lymphocyte invasion and metastases (Tiam-1) has been identified as a marker and anti-cancer drug target for therapy of metastatic bone cancer in individuals afflicted with prostate cancer. The present disclosure provides methods and compounds for inhibiting metastases by disrupting Tiam-1 expression and activity. One particularly preferred compound comprises a disulfomanide of the formula.

  T淋巴细胞侵袭和转移（Tiam-1）已被确定为治疗前列腺癌患者转移性骨癌的标志物和抗癌药物靶点。本公开提供了通过破坏 Tiam-1 的表达和活性来抑制转移的方法和化合物。其中一种特别优选的化合物包括式中的二硫化氢。
• TREATMENT AND OR PREVENTION OF METASTATIC PROSTATE CANCER
  申请人：The Arizona Board Of Regents On Behalf Of The University Of Arizona

  公开号：EP3041469B1

  公开（公告）日：2021-06-30
• TREATMENT AND/OR PREVENTION OF BONE METASTASIS
  申请人：The Arizona Board of Regents on behalf of The University of Arizona

  公开号：US20160213693A1

  公开（公告）日：2016-07-28

  T-lymphocyte invasion and metastases (Tiam-1) has been identified as a marker and anti-cancer drug target for therapy of metastatic bone cancer in individuals afflicted with prostate cancer. The present disclosure provides methods and compounds for inhibiting metastases by disrupting Tiam-1 expression and activity. One particularly preferred compound comprises a disulfomanide of the formula.
• [EN] TREATMENT AND/OR PREVENTION OF BONE METASTASIS<br/>[FR] TRAITEMENT ET/OU PRÉVENTION DE MÉTASTASES OSSEUSES
  申请人：UNIV ARIZONA STATE

  公开号：WO2015035072A1

  公开（公告）日：2015-03-12

  T-lymphocyte invasion and metastases (Tiam-1) has been identified as a marker and anti-cancer drug target for therapy of metastatic bone cancer in individuals afflicted with prostate cancer. The present disclosure provides methods and compounds for inhibiting metastases by disrupting Tiam-1 expression and activity. One particularly preferred compound comprises a disulfomanide of the formula.